Positive Outcomes for Galderma's Injectable Aesthetics Treatments
Recently, Galderma has announced encouraging interim results from a groundbreaking trial designed to assess the effectiveness of its Restylane Lyft™ and Contour™ injections combined with Sculptra in patients suffering from facial volume loss due to medication-induced weight loss. The findings indicate that this innovative combination not only addresses aesthetic concerns effectively but also contributes to high levels of patient satisfaction.
The Growing Concern of Facial Volume Loss
Medication-driven weight loss has surged in popularity, bringing with it unwanted changes to facial appearance. These alterations can manifest as sagging skin, a loss of youthful radiance, and a noticeable change in facial structure, often causing individuals to feel older than their actual age. Such changes can stem from a variety of factors including reduced fat, collagen, and overall skin hydration, leading to a pressing need for effective treatment options.
Empowering Patients with Innovative Solutions
The trial aims to fill a significant gap in current aesthetic treatment options for those affected by these changes. Galderma initiated this study to leverage its comprehensive expertise and advanced product portfolio to address the unique needs of patients and healthcare providers facing the ramifications of medication-related weight loss.
A Comprehensive Clinical Approach
Conducted in the U.S., the phase IV clinical trial utilized the SHAPE Up Holistic Individualized Treatment (HIT™) protocol. This approach allows for tailored treatment regimens that incorporate Sculptra and Restylane derivatives to enhance facial aesthetics by correcting contour deficiencies effectively.
Trial Methodology and Patient Experience
Participants in the trial received a sequence of treatments comprising an initial application of either Restylane Lyft™ or Contour™, paired with Sculptra. Follow-up treatments were strategically planned for weeks four and eight to maximize results. This structured approach ensured optimal patient outcomes while closely monitoring satisfaction and safety metrics.
Encouraging Patient Responses
Three-month interim data from the trial indicated substantial improvements in facial aesthetics among participants experiencing medication-induced facial volume loss. Patients reported enhanced mid-face shape, reduced cheek wrinkles, and a more balanced facial profile. Additionally, skin quality assessments highlighted improvements in skin radiance and hydration following treatment.
Patient Satisfaction and Results
- After just one month, 85% of subjects felt their face appeared more refreshed, while nearly 80% noticed enhanced facial balance, affirming the effectiveness of the SHAPE Up HIT™ approach.
- Results also demonstrated that 89% of participants conveyed a sense of increased attractiveness and satisfaction with their appearance, expressing positive feedback on the natural results achieved.
Importantly, the safety profile of the treatments adhered to established benchmarks, exhibiting no treatment-related adverse events throughout the trial.
The Importance of Comprehensive Patient Care
As medication-related weight loss becomes more prevalent globally, the associated challenges necessitate a holistic approach to patient care. Galderma's extensive experience in dermatology, combined with its specialized injectable treatments, positions the company to meet these emerging needs effectively.
Future Directions and Ongoing Research
An extension of the trial is currently in progress, aimed at evaluating the long-term benefits of these injectable aesthetics treatments. As the clinical study unfolds, further results will provide deeper insights into the lasting effects of the combined treatment method.
About Galderma
Galderma stands as a leader in dermatology, available in about 90 countries. With a focus on innovative, science-driven solutions, Galderma's products span the full spectrum of the dermatology market—ranging from Injectable Aesthetics to Therapeutic Dermatology. Since its inception in 1981, the company has dedicated itself to enhancing skin health and addressing patient needs, partnering closely with healthcare professionals to bring superior outcomes. Galderma is committed to advancing dermatology, ensuring that every individual can achieve their desired skin health.
Frequently Asked Questions
What are the key findings from Galderma's recent trial?
The trial revealed significant improvements in facial aesthetics and high patient satisfaction among those treated for medication-driven facial volume loss using the Restylane and Sculptra combination.
What treatments were part of the clinical trial?
Participants received treatments combining Restylane Lyft™ or Contour™ with Sculptra, following a structured regimen over three months.
How did patients respond to the treatments?
Patients reported enhanced facial appearance, increased satisfaction with their looks, and improvements in skin quality and hydration after treatment.
What is the SHAPE Up HIT™ methodology?
SHAPE Up HIT™ is an individualized treatment approach that optimizes aesthetic results by harnessing the expertise of injectors combined with Galderma's product portfolio.
What is Galderma's commitment to dermatology?
Galderma is dedicated to advancing dermatology by offering innovative, science-based solutions that cater to the diverse needs of skin health while prioritizing patient outcomes.
